“A Randomized, Double-Blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis”. 2021. SKIN The Journal of Cutaneous Medicine 5 (6): s94. https://doi.org/10.25251/skin.5.supp.94.